Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2018
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab in solid tumor (3 cohorts), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 4 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
relatlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03607890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607890.